ArticleInternational journal of clinical oncology2026
Distinct risk profiles of heart failure and non-heart failure major adverse cardiovascular events among patients with early breast cancer: a competing-risk analysis.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular complications are increasingly recognized among patients with breast cancer; however, heart failure has been the primary focus of studies to date. We aimed to evaluate the cumulative incidence of heart failure and other major adverse cardiovascular events among patients with early breast cancer and to identify risk factors.
methodsWe conducted a retrospective cohort study of patients with non-metastatic breast cancer who underwent curative surgery at a tertiary center during 2010-2019. The endpoints were heart failure and other major adverse cardiovascular events (stroke, atrial fibrillation, myocardial infarction, or cardiovascular death). The cumulative incidence was estimated using the cumulative incidence function, and risk factors were evaluated using Fine-Gray competing-risk regression models. Breast cancer recurrence and non-cardiovascular event-related death were treated as competing events.
resultsOver a median follow-up of 7.7 years, heart failure occurred in 24/1,328 (1.8%) patients, whereas other major adverse cardiovascular events occurred in 38 (2.9%). The cumulative incidence of heart failure differed according to perioperative systemic therapy (p = 0.002). Anthracycline use (subdistribution hazard ratio, 2.67; 95% confidence interval, 1.08-6.65; p = 0.034) and trastuzumab use (2.52; 1.00-6.33; p = 0.050) were independently associated with heart failure. By contrast, other major adverse cardiovascular events were associated with age (> 65 years; 3.75; 1.59-8.88; p = 0.003) and cardiovascular risk factors (4.02; 1.77-9.10; p < 0.001).
conclusionsHeart failure was primarily associated with cardiotoxic cancer therapies, and other events by patient-related cardiovascular risk factors. These findings highlight the importance of integrating cardiotoxicity surveillance with long-term cardiovascular risk management in breast cancer survivorship.
Indexed as
Identifiers
42742922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.